JPWO2020264312A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020264312A5 JPWO2020264312A5 JP2021578242A JP2021578242A JPWO2020264312A5 JP WO2020264312 A5 JPWO2020264312 A5 JP WO2020264312A5 JP 2021578242 A JP2021578242 A JP 2021578242A JP 2021578242 A JP2021578242 A JP 2021578242A JP WO2020264312 A5 JPWO2020264312 A5 JP WO2020264312A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- nucleic acid
- combinations
- seq
- isolated nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (50)
5~50アミノ酸長、
6~40アミノ酸長、
8~30アミノ酸長、
10~20アミノ酸長、または
8~11アミノ酸長である、請求項1に記載のペプチド。 the peptide is
5-50 amino acids long,
6-40 amino acids long,
8-30 amino acids long,
2. The peptide of claim 1, which is 10-20 amino acids long, or 8-11 amino acids long.
請求項1~8のいずれか一項に記載の2~250ペプチド、
請求項1~14のいずれか一項に記載の2~100ペプチド、または
請求項1~14のいずれか一項に記載の8~15ペプチドを含む、請求項7~17のいずれか一項に記載の組成物。 2-500 peptides according to any one of claims 1-8,
2-250 peptides according to any one of claims 1-8,
2-100 peptides according to any one of claims 1-14 , or 8-15 peptides according to any one of claims 1-14. The described composition .
組換え酵母細胞、
Saccharomyces属もしくはPichia属から選択された組換え酵母細胞、または
Saccharomyces cerevisiaeもしくはPichia pastorisから選択された組換え酵母細胞である、請求項34に記載の単離された宿主細胞。 the cells
recombinant yeast cells,
35. The isolated host cell of claim 34 , which is a recombinant yeast cell selected from the genera Saccharomyces or Pichia, or a recombinant yeast cell selected from Saccharomyces cerevisiae or Pichia pastoris.
組換え細菌細胞、
Salmonella、Escherichia、Listeria、Shigella、Pseudomonas、Bordetella、Bacillus、Yersinia、Mycobacterium、Lactobacillus、Lactococcus、もしくはVibrioから選択される組換え細菌細胞、または
Salmonella enterica、Escherichia coli、Listeria monocytogenes、Shigella flexneri、Pseudomonas aeruginosa、Bacillus subtilis、Yersinia enterocolitica、Mycobacterium smegmatis、Mycobacterium bovis、Lactococcus lactis、もしくはVibrio anguillarumから選択される組換え細菌細胞である、請求項34に記載の単離された宿主細胞。 the cells
recombinant bacterial cells,
a recombinant bacterial cell selected from Salmonella, Escherichia, Listeria, Shigella, Pseudomonas, Bordetella, Bacillus, Yersinia, Mycobacterium, Lactobacillus, Lactococcus, or Vibrio, or Salmonella enterica, Escherichia coli, Listeria monocytogenes, Shigella flexneri, Pseudomonas aeruginosa, Bacillus 35. The isolated host cell of claim 34 , which is a recombinant bacterial cell selected from subtilis, Yersinia enterocolitica, Mycobacterium smegmatis, Mycobacterium bovis, Lactococcus lactis, or Vibrio anguillarum.
請求項19~30のいずれか一項に記載の単離された核酸分子、請求項31~33のいずれか一項に記載のベクター、請求項34~36のいずれか一項に記載の宿主細胞、またはそれらの組み合わせと、
アジュバント、担体、別の治療薬、及びそれらの組み合わせから選択される追加の成分と、を含む、前記組成物。 A composition comprising:
An isolated nucleic acid molecule according to any one of claims 19-30 , a vector according to any one of claims 31-33 , a host cell according to any one of claims 34-36 . , or a combination thereof, and
and additional ingredients selected from adjuvants, carriers, other therapeutic agents, and combinations thereof.
請求項1~6いずれか一項に記載の治療有効量の少なくとも1つのペプチド、
請求項7~18及び37~39のいずれか一項に記載の治療有効量の組成物、
請求項31~33いずれか一項に記載の治療有効量のベクター、
請求項34~36いずれか一項に記載の治療有効量の宿主細胞、またはそれらの組み合わせを、それを必要とする非ヒト哺乳動物の対象に投与することを含む、前記方法。 A method for treating a non-human mammalian subject infected with a virus, comprising:
a therapeutically effective amount of at least one peptide according to any one of claims 1-6;
a therapeutically effective amount of a composition according to any one of claims 7-18 and 37-39 ;
A therapeutically effective amount of the vector of any one of claims 31-33 ,
37. Said method comprising administering a therapeutically effective amount of the host cells of any one of claims 34-36, or a combination thereof, to a non-human mammalian subject in need thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962868483P | 2019-06-28 | 2019-06-28 | |
US62/868,483 | 2019-06-28 | ||
US201962941381P | 2019-11-27 | 2019-11-27 | |
US62/941,381 | 2019-11-27 | ||
PCT/US2020/039846 WO2020264312A1 (en) | 2019-06-28 | 2020-06-26 | African swine fever vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022538673A JP2022538673A (en) | 2022-09-05 |
JPWO2020264312A5 true JPWO2020264312A5 (en) | 2023-07-04 |
Family
ID=71728905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021578242A Pending JP2022538673A (en) | 2019-06-28 | 2020-06-26 | African swine fever vaccine |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220105170A1 (en) |
EP (1) | EP3990012A1 (en) |
JP (1) | JP2022538673A (en) |
KR (1) | KR20220031028A (en) |
CN (1) | CN113454102A (en) |
AU (1) | AU2020304652A1 (en) |
BR (1) | BR112021026439A2 (en) |
CA (1) | CA3145228A1 (en) |
MX (1) | MX2021015465A (en) |
WO (1) | WO2020264312A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114044806B (en) * | 2020-08-26 | 2023-10-24 | 中国农业科学院兰州兽医研究所 | Polypeptide for promoting pig organism to generate broad-spectrum immune response and application thereof |
CN113845568B (en) * | 2020-08-26 | 2023-08-18 | 中国农业科学院兰州兽医研究所 | Polypeptide for promoting pig organism to generate broad-spectrum acquired immune response and application thereof |
CN111944017B (en) * | 2020-08-26 | 2022-03-04 | 中国农业科学院兰州兽医研究所 | Polypeptide for promoting pig body to generate broad-spectrum acquired immune response and application thereof |
CN112724203A (en) * | 2020-12-30 | 2021-04-30 | 郑州大学 | African swine fever virus p54 protein epitope peptide and application thereof |
CN113061588B (en) * | 2021-05-20 | 2023-08-01 | 军事科学院军事医学研究院军事兽医研究所 | African swine fever virus attenuated strain deleted of I226R gene and live vaccine thereof |
CN113755505B (en) * | 2021-09-30 | 2023-05-02 | 绵阳市游仙区创新科技产业技术研究院 | Vaccine for treating and/or preventing African swine fever virus and preparation method thereof |
WO2024031045A2 (en) * | 2022-08-04 | 2024-02-08 | Malcolm Thomas | Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus |
US11969453B2 (en) | 2023-06-14 | 2024-04-30 | Nae Woi Korea., Ltd. | Horseradish and cinnamon mixed extract composition for suppression of avian viral epidemic diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2551454A1 (en) | 2003-12-24 | 2005-07-07 | Ramot At Tel-Aviv University Ltd. | Antiviral preparations obtained from a natural cinnamon extract |
US8008268B2 (en) * | 2006-07-25 | 2011-08-30 | Merial Limited | Vaccines against vesicular stomatitis |
EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
ES2401276B1 (en) * | 2011-10-04 | 2014-02-19 | Fundació Centre De Recerca En Sanitat Animal | USE OF A GENICAL AND / OR PEPTIDE CONSTRUCTION FOR THE MANUFACTURE OF A VACCINE FOR THE PREVENTION AND / OR TREATMENT OF THE INFECTION CAUSED BY THE VIRUS OF THE AFRICAN SWINE FEVER (VPPA). |
CN103805615A (en) * | 2014-02-19 | 2014-05-21 | 孙洁 | Condon optimized African swine fever virus P54 gene, nucleic acid vaccine and application thereof |
US10279031B2 (en) | 2016-05-11 | 2019-05-07 | Phibro Animal Health Corporation | Composition comprising antigens and a mucosal adjuvant and a method for using |
-
2020
- 2020-06-26 JP JP2021578242A patent/JP2022538673A/en active Pending
- 2020-06-26 CN CN202080001395.0A patent/CN113454102A/en active Pending
- 2020-06-26 AU AU2020304652A patent/AU2020304652A1/en active Pending
- 2020-06-26 WO PCT/US2020/039846 patent/WO2020264312A1/en active Application Filing
- 2020-06-26 MX MX2021015465A patent/MX2021015465A/en unknown
- 2020-06-26 CA CA3145228A patent/CA3145228A1/en active Pending
- 2020-06-26 EP EP20743434.1A patent/EP3990012A1/en active Pending
- 2020-06-26 KR KR1020227002627A patent/KR20220031028A/en unknown
- 2020-06-26 BR BR112021026439A patent/BR112021026439A2/en unknown
-
2021
- 2021-12-17 US US17/554,232 patent/US20220105170A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007271350B2 (en) | Small Streptococcus pyogenes antigens and their use | |
JP5349070B2 (en) | Porphymonasgingivalis polypeptides and nucleotides | |
JP4637350B2 (en) | Group B Streptococcus antigen | |
AU2005254774B2 (en) | Preparation of protective antigen from bacillus anthracis | |
JPWO2020264312A5 (en) | ||
WO2020157222A1 (en) | Inactivated apxia, apxiia and apxiiia toxins | |
Fu et al. | Immunogenicity study of OmpU subunit vaccine against Vibrio mimicus in yellow catfish, Pelteobagrus fulvidraco | |
KR101252911B1 (en) | Attenuated Streptococcus pneumococcus comprising mutated pep27 gene and use the same | |
AU2313199A (en) | Recombinant lipidated psaa protein, methods of preparation and use | |
AU2009323682A1 (en) | Glutamyl tRNA synthetase (GtS) fragments | |
KR20190110090A (en) | Pneumococcal vaccine combining selected alpha-helix domains and proline-rich domains of pneumococcal surface protein A | |
EP1523497A2 (en) | HSP70 FROM i ARTHROBACTER /i | |
RU2022101801A (en) | AFRICAN SWINE FEVER VACCINE | |
AU2002340683B2 (en) | Polypeptides of pseudomonas aeruginosa | |
RU2750894C1 (en) | Vaccine to protect pigs from actinobacillus pleuropneumoniae | |
Stephens et al. | Bacterial patogenesis: Delivering the payload | |
AU2013203639A1 (en) | Small streptococcus pyogenes antiens and their use | |
EP1597274A2 (en) | Hsp60 from arthrobacter | |
CHEN et al. | Expression and Bioinformatics Analysis of Aeromonas hydrophila Outer Membrane TolB Protein | |
CN104470537A (en) | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof | |
AU2003204215B2 (en) | Recombinant Lipidated PsaA Protein, Methods of Preparation and Use | |
Joo-Sung et al. | Molecular cloning and expression of a gene for outer membrane protein H in Pasteurella multocida (A: 3): Production of antisera against the OmpH | |
US7815911B1 (en) | Compositions and methods for treating Yersinia pestis infection | |
US20120076813A1 (en) | USES OF GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS | |
KR20110060690A (en) | Recombinant expression vectors for producing soluble apxiiia proteins |